

Luis Jara-Palomares

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4370982/publications.pdf>

Version: 2024-02-01

144
papers

2,868
citations

236612

25
h-index

205818

48
g-index

154
all docs

154
docs citations

154
times ranked

2946
citing authors

#	ARTICLE	IF	CITATIONS
1	Consenso multidisciplinar para el manejo de la tromboembolia de pulmón. Archivos De Bronconeumologia, 2022, 58, 246-254.	0.4	12
2	Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism. European Respiratory Journal, 2022, 59, 2100412.	3.1	11
3	Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism. Chest, 2022, 161, 524-534.	0.4	14
4	Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. European Heart Journal, 2022, 43, 183-189.	1.0	83
5	Extended anticoagulation treatment for cancer-associated thrombosis: Rates of recurrence and bleeding beyond 6 months: A systematic review. Journal of Thrombosis and Haemostasis, 2022, 20, 619-634.	1.9	22
6	Venous thromboembolism in amyotrophic lateral sclerosis. A prospective quasi-experimental study. Thrombosis Research, 2022, 211, 81-84.	0.8	3
7	Major bleeding in patients with pulmonary embolism presenting with syncope. European Journal of Clinical Investigation, 2022, , e13774.	1.7	0
8	Adjusted D-dimer cutoff levels to rule out pulmonary embolism in patients hospitalized for COPD exacerbation: results from the SLICE trial. Thrombosis Journal, 2022, 20, 10.	0.9	2
9	[Translated article] Multidisciplinary consensus for the management of pulmonary thromboembolism. Archivos De Bronconeumologia, 2022, 58, T246-T254.	0.4	4
10	Effect of Prognostic Guided Management of Patients With Acute Pulmonary Embolism According to the European Society of Cardiology Risk Stratification Model. Frontiers in Cardiovascular Medicine, 2022, 9, 872115.	1.1	2
11	Low-dose apixaban in extended treatment of cancer-associated thrombosis: Less is more?. Journal of Thrombosis and Haemostasis, 2022, 20, 1070-1072.	1.9	1
12	ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly. ERJ Open Research, 2022, 8, 00665-2021.	1.1	2
13	Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study). Cancers, 2022, 14, 2771.	1.7	4
14	2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncology, The, 2022, 23, e334-e347.	5.1	138
15	Timing and characteristics of venous thromboembolism after noncancer surgery. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2021, 9, 859-867.e2.	0.9	7
16	Deep vein thrombosis and brain metastases. Case report and systematic review. Thrombosis Research, 2021, 197, 195-201.	0.8	1
17	Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 168-178.	1.0	10
18	Comparative clinical prognosis of massive and non-massive pulmonary embolism: A registry-based cohort study. Journal of Thrombosis and Haemostasis, 2021, 19, 408-416.	1.9	12

#	ARTICLE	IF	CITATIONS
19	Novel biomarkers to detect occult cancer in patients with unprovoked venous thromboembolism: Rationale and design of the PLATO-VTE study. <i>Thrombosis Update</i> , 2021, 2, 100030.	0.4	3
20	Association between Radiotherapy and Risk of Cancer Associated Venous Thromboembolism: A Sub-Analysis of the COMPASS-CAT Study. <i>Cancers</i> , 2021, 13, 1033.	1.7	12
21	Case-Control Analysis of the Impact of Anemia on Quality of Life in Patients with Cancer: A Qca Study Analysis. <i>Cancers</i> , 2021, 13, 2517.	1.7	3
22	Bleeding risk in hospitalized patients with COVID-19 receiving intermediate or therapeutic doses of thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1981-1989.	1.9	42
23	Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores. <i>TH Open</i> , 2021, 05, e319-e328.	0.7	5
24	Trombosis sintomática de la vena cava: caso clínico y revisión de la literatura. <i>Archivos De Bronconeumología</i> , 2021, 57, 506-509.	0.4	0
25	Multidisciplinary consensus for the management of pulmonary thromboembolism. <i>Archivos De Bronconeumología</i> , 2021, , .	0.4	0
26	Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism. <i>Journal of the American Heart Association</i> , 2021, 10, e021467.	1.6	4
27	Comment on "Severity of pulmonary embolism at initial diagnosis and long-term clinical outcomes: From the COMMAND VTE Registry". <i>International Journal of Cardiology</i> , 2021, 344, 190-191.	0.8	0
28	PICO Questions and DELPHI Methodology for the Management of Venous Thromboembolism Associated with COVID-19. <i>Viruses</i> , 2021, 13, 2128.	1.5	4
29	Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1277.	3.8	28
30	Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism. <i>Internal and Emergency Medicine</i> , 2021, , 1.	1.0	1
31	Venous Thromboembolism in Patients With Autoimmune Disorders: Findings From the RIETE Registry. <i>Angiology</i> , 2020, 71, 131-138.	0.8	6
32	D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry. <i>Journal of Internal Medicine</i> , 2020, 287, 32-41.	2.7	8
33	A Case-Control Analysis of the Impact of Venous Thromboembolic Disease on Quality of Life of Patients with Cancer: Quality of Life in Cancer (Qca) Study. <i>Cancers</i> , 2020, 12, 75.	1.7	20
34	Systolic blood pressure and mortality in acute symptomatic pulmonary embolism. <i>International Journal of Cardiology</i> , 2020, 302, 157-163.	0.8	13
35	Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2020, 8, 353-359.e1.	0.9	10
36	Thromboprophylaxis after renal transplantation and patient risk stratification: The case of mTOR inhibitors. <i>Thrombosis Research</i> , 2020, 195, 100-102.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Screening for occult cancer: where are we in 2020?. Thrombosis Research, 2020, 191, S12-S16.	0.8	4
38	Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: the BACS score. European Respiratory Journal, 2020, 56, 2002336.	3.1	30
39	Screening for Occult Cancer in Patients with Venous Thromboembolism: Past, Present, and Future. Hamostaseologie, 2020, 40, 270-279.	0.9	12
40	Real-Time Dissemination of Aggregate Data on Presentation and Outcomes of Patients With Venous Thromboembolism: The RIETE Infographics Project. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962093120.	0.7	1
41	Prognostic Significance of Incidental Deep Vein Thrombosis in Patients with Cancer Presenting with Incidental Pulmonary Embolism. Cancers, 2020, 12, 2267.	1.7	5
42	Correlation between short-term air pollution exposure and unprovoked lung embolism. Prospective observational (Contamina-TEP Group). Thrombosis Research, 2020, 192, 134-140.	0.8	3
43	Differential biomarker profiles between unprovoked venous thromboembolism and cancer. Annals of Medicine, 2020, 52, 310-320.	1.5	7
44	Venous thromboembolism in solid-organ transplant recipients: findings from the RIETE registry. , 2020, , .		0
45	Mortality after pulmonary embolism in patients with diabetes. Findings from the RIETE registry. European Journal of Internal Medicine, 2019, 59, 46-52.	1.0	9
46	Hospital volume and outcomes for acute pulmonary embolism: multinational population based cohort study. BMJ: British Medical Journal, 2019, 366, l4416.	2.4	41
47	Statin and all-cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE registry. European Journal of Internal Medicine, 2019, 68, 30-35.	1.0	12
48	Extended treatment of cancer-associated thrombosis. Thrombosis Research, 2019, 181, 1-9.	0.8	5
49	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncology, The, 2019, 20, e566-e581.	5.1	458
50	Reply to comment on 'D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis'. British Journal of Cancer, 2019, 120, 473-474.	2.9	0
51	The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease. Clinical Cardiology, 2019, 42, 346-351.	0.7	9
52	Intermittent pneumatic compression plus pharmacological thromboprophylaxis to prevent deep vein thrombosis. Journal of Thoracic Disease, 2019, 11, 1731-1733.	0.6	3
53	Frequency and prognostic impact of acute kidney injury in patients with acute pulmonary embolism. Data from the RIETE registry. International Journal of Cardiology, 2019, 291, 121-126.	0.8	27
54	Vena cava filters in patients presenting with major bleeding during anticoagulation for venous thromboembolism. Internal and Emergency Medicine, 2019, 14, 1101-1112.	1.0	9

#	ARTICLE	IF	CITATIONS
55	Venous thromboembolism in young adults: Findings from the RIETE registry. <i>European Journal of Internal Medicine</i> , 2019, 63, 27-33.	1.0	10
56	Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism. <i>TH Open</i> , 2019, 03, e67-e76.	0.7	15
57	Relationship between type of unprovoked venous thromboembolism and cancer location: An individual patient data meta-analysis. <i>Thrombosis Research</i> , 2019, 176, 79-84.	0.8	8
58	Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years. <i>Scientific Reports</i> , 2019, 9, 20064.	1.6	5
59	Impact of sex, age, and risk factors for venous thromboembolism on the initial presentation of first isolated symptomatic acute deep vein thrombosis. <i>Thrombosis Research</i> , 2019, 173, 166-171.	0.8	32
60	Riesgo de recurrencia tras retirada de la anticoagulación en pacientes con enfermedad tromboembólica venosa no provocada: validación externa del nomograma de Viena y del modelo predictivo DASH. <i>Archivos De Bronconeumología</i> , 2019, 55, 619-626.	0.4	4
61	Anti-Factor Xa levels correlate with recurrent venous thromboembolism and clinically relevant bleeding in patients receiving low-molecular-weight heparin. , 2019, , .		0
62	Role of a clinical prediction score in a chronic thromboembolic pulmonary hypertension rule-out strategy. <i>European Respiratory Journal</i> , 2018, 51, 1702576.	3.1	7
63	Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 360-368.	1.0	14
64	Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism. <i>American Journal of Medicine</i> , 2018, 131, 430-437.	0.6	15
65	Enfermedad tromboembólica venosa y cáncer: un reto para los clínicos. <i>Archivos De Bronconeumología</i> , 2018, 54, 359-360.	0.4	1
66	Sex Differences in Patients With Occult Cancer After Venous Thromboembolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 489-495.	0.7	6
67	Outcomes beyond the Third Month of Anticoagulation in Patients Aged >75 Years with a First Episode of Unprovoked Venous Thromboembolism. <i>TH Open</i> , 2018, 02, e428-e436.	0.7	3
68	Towards a precision medicine in venous thromboembolism associated to lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S3064-S3066.	0.6	1
69	D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis. <i>British Journal of Cancer</i> , 2018, 119, 915-921.	2.9	37
70	Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 551-558.	1.0	2
71	Early Use of Echocardiography in Patients With Acute Pulmonary Embolism: Findings From the RIETE Registry. <i>Journal of the American Heart Association</i> , 2018, 7, e009042.	1.6	31
72	Venous Thromboembolic Disease and Cancer: A Challenge for Clinicians. <i>Archivos De Bronconeumología</i> , 2018, 54, 359-360.	0.4	0

#	ARTICLE	IF	CITATIONS
73	Management appropriateness and outcomes of patients with acute pulmonary embolism. <i>European Respiratory Journal</i> , 2018, 51, 1800445.	3.1	33
74	Clinical Characteristics and Outcomes of Patients with Lung Cancer and Venous Thromboembolism. <i>TH Open</i> , 2018, 02, e210-e217.	0.7	7
75	Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism. <i>PLoS ONE</i> , 2018, 13, e0194673.	1.1	16
76	Response. <i>Chest</i> , 2017, 151, 728-729.	0.4	1
77	Clinically relevant bleeding and thrombotic events in non-cirrhotic splanchnic vein thrombosis. Long-term follow up. <i>Thrombosis Research</i> , 2017, 154, 55-58.	0.8	2
78	Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis. <i>BMJ Open</i> , 2017, 7, e015562.	0.8	14
79	Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism. <i>American Journal of Medicine</i> , 2017, 130, 588-595.	0.6	45
80	Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation. <i>American Journal of Medicine</i> , 2017, 130, 482.e1-482.e9.	0.6	9
81	Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 172-179.	1.0	26
82	Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2017, 167, 410.	2.0	96
83	Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2184-2187.	1.9	22
84	Características clínicas y pronóstico de la tromboembolia pulmonar secundaria al síndrome de clase turista. <i>Archivos De Bronconeumología</i> , 2017, 53, 495-500.	0.4	1
85	Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study. <i>Thrombosis Research</i> , 2017, 157, 90-96.	0.8	105
86	Clinical Characteristics and Prognosis of Pulmonary Embolism Caused by Economy Class Syndrome. <i>Archivos De Bronconeumología</i> , 2017, 53, 495-500.	0.4	3
87	Analysis of noncatheter-associated upper extremity deep venous thrombosis from the RIETE registry. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2017, 5, 18-24.e1.	0.9	15
88	Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. <i>Chest</i> , 2017, 151, 564-571.	0.4	51
89	Calidad de vida en pacientes diagnosticados de embolia de pulmón aguda sintomática. <i>Revista Clínica Española</i> , 2017, 217, 121-122.	0.2	0
90	The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site. <i>American Journal of Medicine</i> , 2017, 130, 337-347.	0.6	83

#	ARTICLE	IF	CITATIONS
91	Noninvasive ventilation for severely acidotic patients in respiratory intermediate care units. BMC Pulmonary Medicine, 2016, 16, 97.	0.8	27
92	Noninvasive ventilation during the weaning process in chronically critically ill patients. ERJ Open Research, 2016, 2, 00061-2016.	1.1	11
93	DVT Management and Outcome Trends, 2001 to 2014. Chest, 2016, 150, 374-383.	0.4	23
94	Analysis of environmental risk factors for pulmonary embolism: A case-crossover study (2001-2013). European Journal of Internal Medicine, 2016, 31, 55-61.	1.0	16
95	Discharge Planning of Neuromuscular Patients with Noninvasive Mechanical Ventilation After Difficult Weaning from Invasive Mechanical Ventilation: From ICU to Home Care. , 2016, , 361-369.		0
96	Trends in the Management and Outcomes of Acute Pulmonary Embolism. Journal of the American College of Cardiology, 2016, 67, 162-170.	1.2	271
97	Treatment of venous thromboembolism in cancer patients with tinzaparin beyond 6 months. TiCAT study. , 2016, , .		0
98	Occult cancer in patients with acute venous thromboembolism: Why, when and where to investigate. , 2016, , .		0
99	Unusual site thrombosis: splanchnic vein thrombosis, management in noncirrhotic. , 2016, , .		0
100	Search predictive factors of recurrence in venous thromboembolic disease associated with cancer after withdrawal of the anticoagulation. HISPALIS study. , 2016, , .		0
101	Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism. Medicine (United States), 2015, 94, e1235.	0.4	43
102	A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the upper extremity. Journal of Thrombosis and Haemostasis, 2015, 13, 1274-1278.	1.9	8
103	The impact of disseminated intravascular coagulation on the outcome of cancer patients with venous thromboembolism. Blood Coagulation and Fibrinolysis, 2015, 26, 709-711.	0.5	5
104	Subsequent arterial ischemic events in patients receiving anticoagulant therapy for venous thromboembolism. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2015, 3, 135-141.e1.	0.9	16
105	Venous thromboembolism in patients immobilised at home. European Respiratory Journal, 2015, 45, 1728-1731.	3.1	5
106	A Prognostic Score to Identify Low-risk Outpatients with Acute Deep Vein Thrombosis in the Lower Limbs. American Journal of Medicine, 2015, 128, 90.e9-90.e15.	0.6	9
107	Fondaparinux in the initial and long-term treatment of venous thromboembolism. Thrombosis Research, 2015, 135, 311-317.	0.8	18
108	Short-term clinical outcome of normotensive patients with acute PE and high plasma lactate. Thorax, 2015, 70, 333-338.	2.7	55

#	ARTICLE	IF	CITATIONS
109	Corrigendum to "Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients" [Thrombosis Research 134 (2014) 617-621]. Thrombosis Research, 2015, 136, 182.	0.8	1
110	A RIETE registry analysis of recurrent thromboembolism and hemorrhage in patients with catheter-related thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2015, 3, 243-250.e1.	0.9	28
111	Lights and shadows of non-invasive mechanical ventilation for chronic obstructive pulmonary disease (COPD) exacerbations. Annals of Thoracic Medicine, 2015, 10, 87.	0.7	9
112	High correlation between 2 flow cytometry platforms in the microparticles analysis using a new calibrated beads strategy. Translational Research, 2015, 166, 733-739.	2.2	6
113	Respiratory intermediate care units: Noninvasive ventilation for severe acidotic patients. , 2015, , .		0
114	Long-term low molecular weight heparin treatment in cancer associated venous thromboembolism patients. , 2015, , .		0
115	Factors associated with mortality and survival in venous thromboembolism and hidden or concurrent cancer. , 2015, , .		0
116	C0211: Prevalence of Metabolic Syndrome and All-Causes Mortality in Patients with Acute Symptomatic Venous Thromboembolism (VTE). Thrombosis Research, 2014, 133, S62.	0.8	1
117	C0246: Quality of Life in Acute Symptomatic Pulmonary Embolism and Low-Risk Prognosis. Thrombosis Research, 2014, 133, S119.	0.8	0
118	Clinical outcome in patients with venous thromboembolism receiving concomitant anticoagulant and antiplatelet therapy. European Journal of Internal Medicine, 2014, 25, 821-825.	1.0	13
119	Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients. Thrombosis Research, 2014, 134, 617-621.	0.8	11
120	Pulmonary Embolism and Concomitant Paradoxical Embolism. A Case Report. Archivos De Bronconeumologia, 2014, 50, 120-122.	0.4	4
121	Tromboembolismo pulmonar y embolia paradójica concomitante. A propósito de un caso. Archivos De Bronconeumologia, 2014, 50, 120-122.	0.4	5
122	D-dimer levels and 90-day outcome in patients with acute pulmonary embolism with or without cancer. Thrombosis Research, 2014, 133, 384-389.	0.8	16
123	C0306: Rivaroxaban for Treatment of Venous Thromboembolism. A Real-Life Perspective in 103 Patients. Thrombosis Research, 2014, 133, S41.	0.8	29
124	Hipertensión pulmonar tromboembólica crónica. Cardiocore, 2013, 48, 60-64.	0.0	2
125	Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism. Thrombosis Research, 2013, 132, 175-179.	0.8	44
126	Factors Associated with elevated Pulmonary Arterial Pressure Levels on the Echocardiographic Assessment in Patients with Prior Pulmonary Embolism. Thrombosis Research, 2013, 131, e191-e195.	0.8	11

#	ARTICLE	IF	CITATIONS
127	Validación de 2 escalas clínicas pronósticas en pacientes con tromboembolia pulmonar aguda sintomática. Archivos De Bronconeumología, 2013, 49, 427-431.	0.4	12
128	Normativa sobre el manejo de las complicaciones respiratorias de los pacientes con enfermedad neuromuscular. Archivos De Bronconeumología, 2013, 49, 306-313.	0.4	48
129	Consenso nacional sobre el diagnóstico, estratificación de riesgo y tratamiento de los pacientes con tromboembolia pulmonar. Archivos De Bronconeumología, 2013, 49, 534-547.	0.4	70
130	Platelet count and outcome in patients with acute venous thromboembolism. Thrombosis and Haemostasis, 2013, 110, 1025-1034.	1.8	17
131	Clinical Manifestations of Sarcoidosis. , 2013, , .		0
132	Chronic Thromboembolic Pulmonary Hypertension Due to Upper-Extremity Deep Vein Thrombosis Caused Thoracic Outlet Syndrome. Archivos De Bronconeumología, 2012, 48, 61-63.	0.4	1
133	Gender differences in lung cancer mortality trends in Andalusia 1975-2008: a joinpoint regression analysis. Medical Oncology, 2012, 29, 1593-1598.	1.2	12
134	Hipertensión pulmonar tromboembólica crónica debida a trombosis venosa profunda de miembro superior por síndrome del desfiladero torácico. Archivos De Bronconeumología, 2012, 48, 61-63.	0.4	4
135	Dyslipidemia as a long-term marker for survival in pulmonary embolism. Revista Portuguesa De Pneumologia, 2011, 17, 205-210.	0.7	3
136	Echocardiographic assessment of pulmonary arterial pressure in the follow-up of patients with pulmonary embolism. Thrombosis Research, 2011, 127, 303-308.	0.8	45
137	Effects of long-term anticoagulant therapy on levels of circulating microparticles in patients with deep venous thrombosis. Blood Coagulation and Fibrinolysis, 2011, 22, 628-629.	0.5	8
138	Lung cancer mortality in Spain: estimating the future burden to the year 2028. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1117-1121.	0.6	15
139	Right Atrium Mass in a 28-Year-Old Patient with Pulmonary Embolism Taking Contraceptives. Journal of Atherosclerosis and Thrombosis, 2011, 18, 829-832.	0.9	3
140	Testing for occult cancer in patients with pulmonary embolism: Results from a screening program and a two-year follow-up survey. Thrombosis Research, 2010, 125, 29-33.	0.8	22
141	Utility of high-resolution computed tomography and BAL in cryptogenic organizing pneumonia. Respiratory Medicine, 2010, 104, 1706-1711.	1.3	26
142	Bronchoalveolar Lavage Findings in Patients With Diffuse Interstitial Lung Disease: Prospective Study of a Cohort of 562 Patients. Archivos De Bronconeumología, 2009, 45, 115-121.	0.4	8
143	Hemorragia digestiva baja asociada a celecoxib. Anales De Medicina Interna, 2003, 20, .	0.1	0
144	Updated Guidelines for the Treatment of Pulmonary Sarcoidosis. , 0, , .		2